Comparative Pharmacology
Head-to-head clinical analysis: ARYNTA versus DALGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYNTA versus DALGAN.
ARYNTA vs DALGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYNTA (pembrolizumab) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2, thereby restoring anti-tumor immune responses.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
400 mg orally once daily
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in healthy adults, prolonged to 6-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Primarily renal elimination (70-80% unchanged), with 10-15% fecal excretion via biliary secretion.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic